Cargando…

Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer

The management of patients with metastatic colorectal cancer (mCRC) has the continuum of care as the treatment paradigm. To date, trifluridine/tipiracil, a biochemically modulated fluoropyrimidine, and regorafenib, a multi-kinase inhibitor, remain the main options for the majority of patients who pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lavacchi, Daniele, Roviello, Giandomenico, Guidolin, Alessia, Romano, Silvia, Venturini, Jacopo, Caliman, Enrico, Vannini, Agnese, Giommoni, Elisa, Pellegrini, Elisa, Brugia, Marco, Pillozzi, Serena, Antonuzzo, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051170/ https://www.ncbi.nlm.nih.gov/pubmed/36982913 http://dx.doi.org/10.3390/ijms24065840

Ejemplares similares

Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience
por: Lavacchi, Daniele, et al.
Publicado: (2021)

Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis
por: Paderi, Agnese, et al.
Publicado: (2021)

Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
por: Fancelli, Sara, et al.
Publicado: (2021)

Liquid biopsy in colorectal cancer: No longer young, but not yet old
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
por: Lavacchi, Daniele, et al.
Publicado: (2023)

A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma
por: Lavacchi, Daniele, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Paderi, Agnese, et al.
Publicado: (2021)

Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study
por: Salvianti, Francesca, et al.
Publicado: (2021)

Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
por: Paderi, Agnese, et al.
Publicado: (2021)

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
por: Gambale, Elisabetta, et al.
Publicado: (2022)

Systemic Sclerosis Association with Malignancy
por: Lepri, Gemma, et al.
Publicado: (2022)

Results of the observational prospective RealFLOT study
por: Giommoni, Elisa, et al.
Publicado: (2021)

Electronic nicotine delivery systems (ENDS): not still ready to put on END
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
por: Rubino, Rossella, et al.
Publicado: (2021)

KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population
por: Fancelli, Sara, et al.
Publicado: (2022)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
por: Hasic Telalovic, Jasminka, et al.
Publicado: (2021)

MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
por: Rodriquenz, Maria Grazia, et al.
Publicado: (2020)

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
por: Giommoni, Elisa, et al.
Publicado: (2021)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma
por: Pasqui, Adriano, et al.
Publicado: (2022)

Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer
por: Liu, Shuai, et al.
Publicado: (2022)

Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level
por: Pillozzi, Serena, et al.
Publicado: (2021)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience
por: Nobili, Stefania, et al.
Publicado: (2020)

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
por: Procaccio, Letizia, et al.
Publicado: (2023)

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer
por: Song, Yan, et al.
Publicado: (2021)

Case report: PRES associated with fruquintinib in a patient with metastatic colon cancer
por: Wang, Lu, et al.
Publicado: (2023)

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
por: Peng, Zhi, et al.
Publicado: (2020)

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer
por: Shu, Yefei, et al.
Publicado: (2021)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Induction Chemotherapy Followed by Pleurectomy Decortication and Hyperthermic Intraoperative Chemotherapy (HITHOC) for Early-Stage Epitheliod Malignant Pleural Mesothelioma—A Prospective Report
por: Bongiolatti, Stefano, et al.
Publicado: (2021)

Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review
por: Xu, Xiaojing, et al.
Publicado: (2022)

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer
por: Li, Qingli, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_99fhg2tppce0v2d7h2u2hd18av